Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2014-01-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 313.4KB
Interim / Quarterly Report Classification · 100% confidence The document is an Appendix 4C quarterly report lodged with the ASX, covering the quarter ended 31 December 2013. It contains detailed cash flow statements, explanations of cash movements, payments to directors, financing facilities, and compliance statements. The Appendix 4C is a standard quarterly cash flow report required by the ASX for entities admitted on the basis of commitments. The document is about 7,450 characters long, which is sufficient to contain substantive financial data. It is not an announcement of a report but the report itself. This fits the definition of an Interim / Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year, including actual financial statements and analysis. Therefore, the correct classification is IR. Q2 2014
2014-01-30 English
FDA lifts hold on smoking cessation trial 1 page 22
Regulatory Filings Classification · 95% confidence The document is a media announcement from Invion Limited dated 29 January 2014. It announces that the FDA has lifted a clinical hold on a phase II clinical trial for a drug. The content focuses on regulatory and clinical trial updates rather than financial results, management changes, or shareholder information. The document is short (3168 characters) and reads as a news release or announcement rather than a detailed report or filing. There is no indication of financial data, voting results, or regulatory certifications. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2014-01-28 English
Smoking cessation study hold 1 page 244.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX media announcement dated 20 December 2013 regarding a clinical trial hold by the FDA on Invion Limited's Phase II smoking cessation study. It discusses regulatory feedback, study protocol changes, and company strategy to address the FDA's concerns. There are no financial statements, earnings data, or detailed financial analysis. The document is a regulatory update or announcement about clinical trial status rather than a financial report or detailed investor presentation. It is relatively short (4475 characters) and serves as a public announcement of a regulatory event affecting the company. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2013-12-19 English
Appendix 3B Lapse of unlisted options 12 pages 500.9KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to securities issuance. It includes detailed information about share options, securities issued, shareholder approvals, and placement capacities under ASX listing rules. The content focuses on capital raising activities, securities issuance, and compliance with regulatory requirements for new securities. There is no indication that this is a full financial report, audit report, earnings release, or management discussion. Instead, it is a regulatory announcement about capital changes and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2013-11-27 English
AGM Chairman's Address and CEO presentation 32 pages 1.2MB
AGM Information Classification · 100% confidence The document is an ASX announcement dated 22 November 2013, titled 'INVION LIMITED AGM CHAIRMAN’S ADDRESS & CEO PRESENTATION'. It contains the Chairman's address to shareholders and the CEO's presentation for the 2013 Annual General Meeting (AGM). The content includes detailed speeches, company updates, clinical trial progress, management team information, and pipeline details, all typical of materials presented at an AGM. The document is lengthy (15,000 characters) and contains substantive presentation content rather than just an announcement of a report or a brief summary. There is no indication that this is a full annual report or financial statements, nor is it a transcript of a call or a regulatory filing. The presence of the Chairman's address and CEO presentation specifically for the AGM aligns with the category AGM Information (AGM-R).
2013-11-21 English
Results of Meeting 1 page 225.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 22 November 2013 titled 'INVION LIMITED RESULTS OF ANNUAL GENERAL MEETING'. It details the voting results for each resolution put to the AGM, including the number of votes for, against, abstentions, and proxies. The content focuses exclusively on the outcome of shareholder votes at the AGM, with no financial statements or management discussion. The document length is short (1554 characters) and it is clearly a formal announcement of voting results rather than the AGM materials themselves or the full annual report. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2013-11-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.